JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
Thiazovivin is a novel ROCK inhibitor with IC50 of 0.5 μM in a cell-free assay, promotes hESC survival after single-cell dissociation. Improves the efficiency of fibroblast reprogramming and induction of iPSCs.
Thiazovivin is a potent and selective inhibitor of Rho kinase (ROCK) activity, a key player in cytoskeletal contraction and rearrangement. As ROCK inhibition occurs, human embryonic stem cell survival increases through enhanced cell-ECM attachment via E-cadherin signaling (Xu, et al.), in addition to allowing for an environment for improved human iPSCs from fibroblasts when used in combination with ALK5 inhibitor SB 431542 and MEK inhibitor PD0325901 (Lin, et al.). The addition of Thiazovivin also creates more effective conditions for the reprogramming of cord blood mononuclear cells into iPSCs (Hu, et al.).
Applications: cellular reprogramming, mouse embryonic fibroblasts into chemically induced neural stem cells, improves the efficiency of iPSC generation Molecular name: Thiazovivin, ROCK inhibitor Purity: Greater than 95% by LCMS
Keywords: Thiazovivin, Thiazovivin supplier, stem cells, reprogramming, dedifferentiation, induced pluripotent stem cells, ipscs, hesc, neural, fibroblasts, reprogramming, rho-kinases, cell proliferation
PDF | Download Captivate Bio's 2024 New Products & Services brochure. Highlighting new reagent sourcing, storage services, salt solutions, water, cytokines and growth factors to support life science research.
PDF | EverCell Bio and Captivate Bio have teamed up to provide a single source solution for stem cell modeling services and ongoing product support to accelerate translational and therapeutic discoveries. Download our brochure here.
This research spotlight highlights the superior cryoprotective capacity of the CEPT method and the survival and functionality of preserved hPSCs.